Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN - PubMed (original) (raw)

Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN

I C Gray et al. Br J Cancer. 1998 Nov.

Free PMC article

Abstract

The chromosomal region 10q23-24 is frequently deleted in a number of tumour types, including prostate adenocarcinoma and glioma. A candidate tumour-suppressor gene at 10q23.3, designated PTENor MMAC1, with putative actin-binding and tyrosine phosphatase domains has recently been described. Mutations in PTEN have been identified in cell lines derived from gliomas, melanomas and prostate tumours and from a number of tumour specimens derived from glial, breast, endometrial and kidney tissue. Germline mutations in PTEN appear to be responsible for Cowden disease. We identified five PTEN mutations in 37 primary prostatic tumours analysed and found that 70% of tumours showed loss or alteration of at least one PTEN allele, supporting the evidence for PTEN involvement in prostate tumour progression. We raised antisera to a peptide from PTEN and showed that reactivity occurs in numerous small cytoplasmic organelles and that the protein is commonly expressed in a variety of cell types. Northern blot analysis revealed multiple RNA species; some arise as a result of alternative polyadenylation sites, but others may be due to alternative splicing.

PubMed Disclaimer

Similar articles

• Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas.
  Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, Boyd J. Rhei E, et al. Cancer Res. 1997 Sep 1;57(17):3657-9. Cancer Res. 1997. PMID: 9288766
• Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.
  Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, Isaacs WB, Bova GS. Suzuki H, et al. Cancer Res. 1998 Jan 15;58(2):204-9. Cancer Res. 1998. PMID: 9443392
• Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.
  Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV. Steck PA, et al. Nat Genet. 1997 Apr;15(4):356-62. doi: 10.1038/ng0497-356. Nat Genet. 1997. PMID: 9090379
• The tumour suppressor PTEN: involvement of a tumour suppressor candidate protein in PTEN turnover.
  Maehama T, Okahara F, Kanaho Y. Maehama T, et al. Biochem Soc Trans. 2004 Apr;32(Pt 2):343-7. doi: 10.1042/bst0320343. Biochem Soc Trans. 2004. PMID: 15046605 Review.
• PTEN: a tumour suppressor that functions as a phospholipid phosphatase.
  Maehama T, Dixon JE. Maehama T, et al. Trends Cell Biol. 1999 Apr;9(4):125-8. doi: 10.1016/s0962-8924(99)01519-6. Trends Cell Biol. 1999. PMID: 10203785 Review.

Cited by

• Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment.
  Brana I, Siu LL. Brana I, et al. BMC Med. 2012 Dec 11;10:161. doi: 10.1186/1741-7015-10-161. BMC Med. 2012. PMID: 23232172 Free PMC article. Review.
• Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner.
  Song MS, Carracedo A, Salmena L, Song SJ, Egia A, Malumbres M, Pandolfi PP. Song MS, et al. Cell. 2011 Jan 21;144(2):187-99. doi: 10.1016/j.cell.2010.12.020. Cell. 2011. PMID: 21241890 Free PMC article.
• Targeting the PI3-kinase/Akt/mTOR signaling pathway.
  Hassan B, Akcakanat A, Holder AM, Meric-Bernstam F. Hassan B, et al. Surg Oncol Clin N Am. 2013 Oct;22(4):641-64. doi: 10.1016/j.soc.2013.06.008. Epub 2013 Aug 6. Surg Oncol Clin N Am. 2013. PMID: 24012393 Free PMC article. Review.
• ATM Kinase Inhibition Preferentially Sensitises PTEN-Deficient Prostate Tumour Cells to Ionising Radiation.
  Hanna C, Dunne VL, Walker SM, Butterworth KT, McCabe N, Waugh DJJ, Kennedy RD, Prise KM. Hanna C, et al. Cancers (Basel). 2020 Dec 30;13(1):79. doi: 10.3390/cancers13010079. Cancers (Basel). 2020. PMID: 33396656 Free PMC article.
• PTEN stabilizes TOP2A and regulates the DNA decatenation.
  Kang X, Song C, Du X, Zhang C, Liu Y, Liang L, He J, Lamb K, Shen WH, Yin Y. Kang X, et al. Sci Rep. 2015 Dec 10;5:17873. doi: 10.1038/srep17873. Sci Rep. 2015. PMID: 26657567 Free PMC article.

References

1. 1. Nature. 1974 Feb 15;247(5441):457-61 - PubMed
2. 1. Science. 1997 Mar 28;275(5308):1943-7 - PubMed
3. 1. Cancer Res. 1997 Jun 1;57(11):2124-9 - PubMed
4. 1. Nat Genet. 1997 Aug;16(4):333-4 - PubMed
5. 1. Cancer Res. 1997 Sep 1;57(17):3657-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Nature Publishing Group
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program